THOR News and Press, Synthorx Inc. From 12/09/19

Synthorx (NASDAQ: THOR ) +169%  on being acquired by Sanofi. More news on: Synthorx, Inc., XBiotech Inc., ArQule, Inc., Stocks on the move, Read more ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . U.S. stock index futures are suggesting a pause from Friday's job-fueled rally as investors prepare for a series of major risk ev...

Bolstering its immuno-oncology pipeline, Sanofi (NASDAQ: SNY ) will acquire all of the outstanding shares of Synthorx (NASDAQ: THOR ) for $68 per share in cash, representing a 172% premium to the latter's closing price on Dec. 6. More news on: Sanofi, Synthorx, Inc., Healthcare stocks ne...

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at multiple upcoming investor conferences: Live webcasts of t...

Synthorx (NASDAQ: THOR ): Q3 GAAP EPS of -$0.38 beats by $0.12 . More news on: Synthorx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update for the third quarter ended September 30,...

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data highlighting THOR-809 will be presented at the American College of ...

SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the presentation of three  posters at the upcoming Society for Immunotherapy of Canc...

Investors are optimistic heading into Winnebago 's (NYSE: WGO) fourth-quarter earnings report. The leading recreational vehicle manufacturer is sure to announce its first annual sales decline in years as the RV industry contracts following a nine-year record run. However, Winnebago's operatin...

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology product candidate, THOR-707, will be presented...